I assume Avita one is class II resubmission with minimal effort fix it and it will get the approval in anytime from now, if shorts playing, that’s going to be a loose for them…
- Class I resubmissions: If the FDA determines that additional information or data from the sponsor can easily address minor deficiencies in their application, it is classified as a class 1 resubmission. Upon resubmission, the FDA has two to three months to review these applications.
- Class II resubmissions: If the FDA determines that significant changes or new data are needed to address sponsor deficiencies in their application, it is classified as a class 2 resubmission. Upon resubmission, the FDA has six months to review these applications.
Ann: AVITA Medical to Announce First Quarter 2024 Results, page-6
-
- There are more pages in this discussion • 189 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
0.010(0.41%) |
Mkt cap ! $160.4M | |||
| Open | High | Low | Value | Volume |
| $2.42 | $2.45 | $2.41 | $562.3K | 231.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 82002 | $2.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 16 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVH (ASX) Chart |